Big maneuvers among the big American companies with M&A operations. Meanwhile, the Italian Recordati is thinking about targeted M&A operations in its new plan to 2025
The US pharmaceutical giant will pay $229 for each share in cash. And the titles fly to Wall Street
Faced with the decline of the pandemic and consequently of profits and stock market performance, the pharma giants compete in the courts: here's what's at stake
According to Moderna, Pfizer and BioNTech would have used the mRna technology deposited by the company between 2010 and 2016
Global Blood Therapeutics stock has gained more than 90% of its value on the Nasdaq from Thursday to today
Pfizer will pay $148,5 per share, all in cash. The closing is expected in the first months of 2023 - Biohaven shares fly to Wall Street and are close to the offer price
In the US, the Pfizer vaccine for children under 5 could be available by the end of February - The dose will be one tenth of that expected for adults: 3 micrograms
We are talking about Arena Pharmaceuticals, whose shares will be purchased at 100 dollars each, with a 100,2% premium. It is the second maxi acquisition in the sector after that of Novartis at the end of November
With the third dose, the protection against the development of severe symptoms goes back to 93%. For the unvaccinated, the risk of death is 16 times higher than for those vaccinated with the booster
The CEO of the US pharmaceutical giant: "Three doses of vaccine are effective against Omicron" - According to a laboratory study, the booster dose increases neutralizing antibody titers by 25 times
Scientist Stéphane Bancel speaks and cools the enthusiasm of the markets: it will not be so easy to counter Omicron - more optimistic Pfizer with record turnover. But it is controversy with South Africa on the power of Big Pharma
The dose will be reduced compared to that used in people aged 12 and over
Pharmaceuticals in free fall on Wall Street, with Moderna and BionTech losing almost 20% - Pfizer bucking the trend, which flies after the news on the anti-Covid drug
The American Big Pharma, with the collaboration of BioNTech, collects the extraordinary result of the best-selling vaccine in the history of medicine. Logistics and science are the basis of the resounding success. US green light for vaccination for children aged 5-11
The third dose of the anti-Covid vaccine could soon become necessary for everyone - Reservations are open for some categories of citizens in the meantime - Here is the complete guide
"The school must no longer close", says the President of the Republic - Meanwhile, Pfizer announces that the vaccine is "safe and effective" on children aged 5 to 11
While the hypothesis of the third dose against the Delta variant seems to take shape, the two pharmaceutical companies proceed to collect: according to the FT, they would have renegotiated the contracts with Brussels (which it neither confirms nor denies)
In the light of the positive data of the epidemiological curve and taking into account the millions of doses of vaccine arriving, the CTS has decided to administer the Oxford vaccine only to the over 60s and continue for the younger ones in…
The EMA confirms what AIFA said: postponing the second dose is possible, despite Pfizer's different opinion - Meanwhile, the use of the vaccine is also being evaluated on adolescents between 12 and 15 years of age
The Food and Drug Administration has concluded the trial on the 12-15 year age group. The EMA will instead pronounce itself in the month of June
Pfizer sold vaccines worth 3,5 billion in the first quarter, estimates for 2021 rise from 15 to 26 billion - Revenues and earnings per share up sharply in the first three months of the year
AstraZeneca (and probably also J&J) will not be administered to the under 60s, therefore the plans of many countries change. Denmark suspends AstraZeneca definitively. EU-Pfizer agreement for 50 million new doses. The moves of France and Germany
The decisive week has begun which could give a turning point to the Italian vaccination campaign - The first doses of the Johnson & Johnson single-dose are expected to arrive tomorrow - Here are all the incoming deliveries
The serum would protect adolescents even better than adults, with the same (minimal) side effects. Now the pharmaceutical company will send the results of the study to the FDA for the green light for administration.
Signed a contract for an additional 4 million doses of the Pfizer-Biontech vaccine - 532 more doses for Italy - The go-ahead is coming to Johnson and Johnson who denied the cuts - Here are all the doses arriving in Italy
What are the most effective vaccines in the fight against Covid? And which ones are easier to use? Here is a first evaluation, pending the Johnson & Johnson vaccine
Between vaccines, treatments and diagnostic tests, pharmaceutical stocks have been within the attention of investors for months. Who earned the most and why?
the vaccine dossier on the table of the EU Council: We will enforce the contracts". The agreement signed with Europe does not provide for automatic penalties in the event of non-compliance. Meanwhile, all vaccinations are postponed, starting with those of the over 80s
Based on the contracts, the only binding deadline is the end of the first quarter and the pharmaceutical company assures that by then it will have made up for the delay - However, this may not be enough for Italy. Lazio stops
The renewed dangers of the pandemic and Pfizer's announcement that it will temporarily reduce the doses available to Europe reverse the course of the stock exchanges which are all falling downwards - Piazza Affari loses 1,13% but defends itself better than the other lists: they retreat …
The first doses of the British pharmaceutical company, expected in January, will not be delivered before late February - To compensate, the supplies arriving from Pfizer and Moderna will be increased
After the green light from Aifa, the first 9.750 doses will arrive at the Spallanzani hospital in Rome on the morning of December 26 and will be quickly sorted to allow all of Italy to participate in "Vaccine Day" the following day
The long-awaited go-ahead for the Pfizer vaccine from the European Medicines Agency has finally arrived - Tonight the OK from the Commission - von der Leyen: "Decisive moment" - Shipments from 24 December, the serum will arrive in Rome on 26
While anti-Covid vaccinations begin in London, in the US the Food and Drug Administration has established that the Pfizer and BioNTech drug "does not raise any particular safety problems". Thursday the final ok for the administration.
Pfizer's announcement of further effectiveness of its anti-Covid vaccine pleases the markets, especially the European ones and Piazza Affari is once again the best stock exchange - Banks and Generali also do well on its Investor Day
It is a battle between the two American giants for the anti Covid vaccine. A new announcement has arrived from Pfizer: "Phase 3 completed, 95% effectiveness. As the derby goes on, a surprise could come from the British AstraZeneca.
Sparks on all the Stock Exchanges after the announcement of a vaccine by the American Moderna more effective and simpler than that of Pfizer - Wall Street opens sharply and Piazza Affari closes with an increase of almost 2% ...
AstraZeneca and Johnson & Johnson have anticipated their vaccine will be nonprofit, but Pfizer and others have already set the price. A great deal is foreseen but also an impressive effort for the logistics and distribution of vaccines: from…
The Pfizer vaccine should arrive in Italy at the end of January and the AstraZeneca vaccine could also be ready by the same month - The US drug authority has approved the use of Eli Lilly's anti-Covid antibody treatment…
Pfizer's announcement that its anti-Covid vaccine is effective drives stock markets all over the world crazy - Piazza Affari gains 5,4%, driven by the boom of Pirelli (+13%), Unicredit, Leonardo and Eni - In addition to pharma…
AstraZeneca could collect up to 1,6 billion dollars from the operation, also thanks to the rights to the drugs involved
The acquisition of the Californian group allows Pfizer to add to its portfolio the prostate cancer drug Xtandi, which has already generated $2 billion in revenues with its first sales.
The American pharmaceutical giant does not expect an impact of the transaction on its 2016 accounts but expects it to be slightly dilutive of the adjusted earnings per share (eps) in 2017 with growth in EPS starting in 2018 and increasing in subsequent years.
The decision came after the US Treasury Department introduced new limits for the so-called tax inversion, i.e. a merger aimed at moving the headquarters to countries with more favorable tax treatment.
The merger should be completed in the second half of 2016 - The agreement will bring tax advantages for the US company given that the company's headquarters should be in Ireland.
The US automaker closed the third quarter with growing profits and revenues, but did not meet Wall Street's expectations - Profits down for Pfizer, which however beats estimates and revises its 2015 targets…
Pfizer will not make a new offer for the British pharmaceutical giant Astrazeneca: "The offer of May 18 is the definitive one".
The decision of the British pharmaceutical group to say no to a 120 billion dollar offer from Pfizer has not pleased all the shareholders: some are asking for the negotiations to be reopened.
The British pharmaceutical company claims that even the new proposal of the US competitor (which came to offer 117 billion, after the first two attempts at 100 and 106 billion), underestimates the company and its prospects - The AstraZeneca board would be…
Piazza Affari starts negative this morning because 7 billion coupons arrive - Meanwhile 4 mega-deals are animating the international scene: At&t buys Direct, Deutsche Bank recapitalizes, Pfizer raises its offer for Astrazeneca and Siemens unveils its moves for Alstom - Wait…
While waiting for Pfizer's next move, in the US there is trepidation for the possible umpteenth exit from American soil of one of the country's largest companies - Here are the reasons that push Pfizer to up the ante and who will emerge defeated…
"The offer continues to significantly underestimate the value of the company", reads a press release - The British pharmaceutical group also specifies that the new refusal was decided "without hesitation".
In January, the British group rejected an initial offer from Pfizer at 46,61 pounds per share for a total of $99 billion, judging the company "significantly" undervalued.
